Navigation Links
Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents

New Patents Announced for Methods of Cloning Livestock From Differentiated Donor Cells

AUSTIN, Texas, Dec. 11 /PRNewswire-USNewswire/ -- Start Licensing, Inc. (Start) announced today that the U.S. Patent and Trademark Office has granted U.S. Patent Nos. 7,304,204 and 7,307,198 covering methods of cloning ungulate animals, fetuses and embryos using differentiated cells. These two patents are part of a portfolio of patents and patent applications owned by Roslin Institute that are directed to foundational somatic cell nuclear transfer (SCNT) cloning technology developed at Roslin Institute for the cloning of Dolly the sheep. This portfolio is exclusively licensed to Start for all non-human animal cloning applications.

In addition, the Patent Office has also recently issued notices of allowance for related patent applications in the portfolio, including U.S. Patent Application Nos. 09/650,194 and U.S. 09/989,126 directed to methods of cloning ungulate animals, fetuses and embryos, and of producing mammalian inner cell mass cells. The allowance of these two applications is a direct result of patent interference proceedings initiated at the Patent Office between the 09/650,194 and 09/989,126 applications and U.S. Patents 5,945,577 and 6,234,970, owned by the University of Massachusetts and exclusively licensed to Advanced Cell Technology. A patent interference is a proceeding conducted by the Patent Office when two or more parties claim the same invention in patent filings. Under U.S. law, only the party that is first to invent a new technology is entitled to a patent. The interference proceedings were decided in favor of the 09/650,194 and 09/989,126 applications and judgment was entered against the 5,945,577 and 6,234,970 patents.

Other patents in the portfolio include recently granted U.S. Patent No. 7,232,938 directed to method of cloning ungulates through fusion or microinjection of a quiescent ungulate donor cell. Metabolic changes indicative of cell quiescence include, among other things, the presence of condensed chromatin.

"These patents and allowed applications further strengthen our animal cloning patent position," said Jonathan Thatcher, Chairman of Start Licensing. "The technology covered by the Roslin patents and patent applications has been widely adopted and has increasingly important commercial applications for a wide variety of industries, including agriculture and healthcare. It has been used to clone a broad range of species including cattle, sheep, pigs, goats, horses, mice, rats, rabbits, cats and dogs."

About Start Licensing

Start is a joint venture of Geron Corporation (NASDAQ: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep. Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.

For more information, call Natalie Garrett, Start Licensing/Turner Strategies, 202-466-9633

SOURCE Start Licensing, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Underage drinking starts before adolescence
2. Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids
3. Parents Shouldnt Forget Scoliosis Checks as School Starts
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Motherhood(R) Maternity Joins March of Dimes to Give Babies a Healthy Start in Life
6. LeMaitre Vascular to Start Italian Sales Force
7. Blunt: Time to Stop the Politics on SCHIP, and Start the Negotiations
8. Congress Starts Hearings on FDAs Control of Tobacco
9. Jane Fonda and Bright Starts(TM) Celebrates Pink Power Moms at Susan G. Komen for the Cure Pink Tie Ball
10. Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion
11. Penn wins $5M to start center for ethical, legal and social implications research
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: